Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3858-3868

  Prokaeva, Tatiana ^a   Spencer, Brian ^a   Kaut, Maurya ^a   Ozonoff, Al ^b   Doros, Gheorghe ^b   Connors, Lawreen H ^a   Skinner, Martha ^a   Seldin, David C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RNA;

ADULT; AGED; AMYLOIDOSIS; ARTHROPATHY; ARTICLE; BONE DISEASE; BONE MARROW BIOPSY; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; KAPLAN MEIER METHOD; MACROGLOSSIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOFT TISSUE DISEASE; SPINE DISEASE; SUBMANDIBULAR GLAND; SURVIVAL RATE; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS, FAMILIAL; BONE AND BONES; CARPAL TUNNEL SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INCIDENCE; JOINTS; MACROGLOSSIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SUBMANDIBULAR GLAND; SUBMANDIBULAR GLAND DISEASES; TONGUE;

EID: 36048939324     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22959     Document Type: Article

References (50)

1. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-62.
2. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
3. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
4. Dhodapkar MV, Jagannath S, Vesole D, Munshi N, Naucke S, Tricot G, et al. Treatment of AL-amyloidosis with dexamethasone plus α interferon. Leuk Lymphoma 1997;27:351-6.
5. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241-6.
6. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-61.
7. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase II trial. Blood 2007;109:492-6.
8. Gerster JC, Landry M, Dudler J. Scleroderma-like changes of the hands in primary amyloidosis. J Rheumatol 2000;27:2275-7.
9. Fujishima M, Komatsuda A, Imai H, Wakui H, Watanabe W, Sawada K. Amyloid arthropathy resembling seronegative rheumatoid arthritis in a patient with IgD-κ multiple myeloma. Intern Med 2003;42:121-4.
10. Gordon DA, Pruzanski W, Ogryzlo MA, Little HA. Amyloid arthritis simulating rheumatoid disease in five patients with multiple myeloma. Am J Med 1973;55:142-54.
11. Gogel HK, Searles RP, Volpicelli NA, Cornwell GG III. Primary amyloidosis presenting as Sjögren's syndrome. Arch Intern Med 1983;143:2325-6.
12. Schlesinger I. Multiple myeloma and AL amyloidosis mimicking Sjögren's syndrome. South Med J 1993;86:568-9.
13. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
14. Liepnieks JJ, Burt C, Benson MD. Shoulder-pad sign of amyloidosis: structure of an Ig κ III protein. Scand J Immunol 2001;54:404-8.
15. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-43.
16. Comenzo RL, Michelle D, LeBlanc M, Wally J, Zhang Y, Kica G, et al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 1998;38:60-9.
17. Welschof M, Terness P, Kolbinger F, Zewe M, Dubel S, Dorsam H, et al. Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J Immunol Methods 1995;179:203-14.
18. Giudicelli V, Chaume D, Lefranc MP. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004;32(Web Server issue):W435-40.
19. Lossos IS, Tibshirani R, Narasimhan B, Levy R. The inference of antigen selection on Ig genes. J Immunol 2000;165:5122-6.
20. Lossos IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000;95:1797-803.
21. Su JQ, Wei LJ. Nonparametric estimation for the difference or ratio of median failure times. Biometrics 1993;49:603-7.
22. Kyle RA, Eilers SG, Linscheid RL, Gaffey TA. Amyloid localized to tenosynovium at carpal tunnel release: natural history of 124 cases. Am J Clin Pathol 1989;91:393-7.
23. Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, et al. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature [review]. Clin Rheumatol 2006;25:3-15.
24. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.
25. Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996;60:655-60.
26. Leach DB, Hester TO, Farrell HA, Chowdhury K. Primary amyloidosis presenting as massive cervical lymphadenopathy with severe dyspnea: a case report and review of the literature. Otolaryngol Head Neck Surg 1999;120:560-4.
27. Kahn H, Strauchen JA, Gilbert HS, Fuchs A. Immunoglobulin-related amyloidosis presenting as recurrent isolated lymph node involvement. Arch Pathol Lab Med 1991;115:948-50.
28. Ko HS, Davidson JW, Pruzanski W. Amyloid lymphadenopathy. Ann Intern Med 1976;85:763-4.
29. Segalov E, Gibson J, Joshua DE, Kronenberg H. Primary amyloidosis co-presenting with cervical and massive intra-abdominal lymphadenopathy. Leuk Lymphoma 1995;19:519-20.
30. Kutlay S, Hasan T, Keven K, Nergizoglu G, Ates K, Karatan O. Primary amyloidosis presenting with massive generalized lymphadenopathy. Leuk Lymphoma 2002;43:1501-3.
31. Ben Ghorbel I, Houman MH, Lamloum M, Romdhane NB, Daniel L, M'Timet B, et al. Pseudotumoral adenopathies, an unusual means of detecting systemic amyloidosis. Rev Med Interne 1999;20:1037-40. In French.
32. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-8.
33. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888-93.
34. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001;98:714-20.
35. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, et al. Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (λIII) as a new amyloid-associated germline gene segment. Blood 2002;100:948-53.
36. Lafforgue P, Senbel E, Figarella-Branger D, Boucraut J, Horschowsky N, Pellissier JF, et al. Systemic amyloidosis AL with temporal artery involvement revealing lymphoplasmacytic malignancy in a man presenting as polymyalgia rheumatica. Ann Rheum Dis 1993;52:158-60.
37. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003;101:3801-8.
38. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501-5.
39. Raubenheimer EJ, Dauth J, Pretorius FJ. Multiple myeloma and amyloidosis of the tongue. J Oral Pathol 1988;17:554-9.
40. Reinish EI, Raviv M, Srolovitz H, Gornitsky M. Tongue, primary amyloidosis, and multiple myeloma. Oral Surg Oral Med Oral Pathol 1994;77:121-5.
41. Bukhari M, Freemont AJ, Noble J, Jayson MI. Erosive amyloidosis of the wrist and knee associated with oligoclonal bands. Br J Rheumatol 1997;36:494-7.
42. Curran JF, Ellman MH, Brown NL. Rheumatologic aspects of painful conditions affecting the shoulder. Clin Orthop Relat Res 1983:27-37.
43. Fautrel B, Fermand JP, Sibilia J, Nochy D, Rousselin B, Ravaud P. Amyloid arthropathy in the course of multiple myeloma. J Rheumatol 2002;29:1473-81.
44. Chapin JE, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 2005;31:266-72.
45. Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol 1998;43:719-28.
46. Fukuda T, Takao M, Uchida T, Iwanaga S, Hayashi K, Okimoto T. High attenuation lymphadenopathy caused by amyloidosis. Br J Radiol 1997;70:213-4.
47. Weinfeld A, Stern MH, Marx LH. Amyloid lesions of bone. Am J Roentgenol Radium Ther Nucl Med 1970;108:799-805.
48. Axelsson U, Hallen A, Reusing A. Amyloidosis of bone: report of two cases. J Bone Joint Surg Br 1970;52:717-23.
49. Wiernik PH. Amyloid joint disease. Medicine (Baltimore) 1972;51:465-79.
50. Kramer MR, van Dijk JM, Hadas I, Hershko C. Destructive bone lesions in primary amyloidosis. Postgrad Med J 1986;62:1037-41.